Search
Lung Cancer Clinical Trials in Orange City, FL
A listing of 16 Lung Cancer clinical trials in Orange City, FL actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
13 - 16 of 16
The city of Orange City, Florida, currently has 16 active clinical trials seeking participants for Lung Cancer research studies.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
Studying an Investigational Virus Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Healthy
Interested in vaccine studies
All Conditions
Preventative Trials
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Trial
Evaluating an Investigational Treatment for Hidradenitis Suppurativa
Recruiting
The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.
Conditions:
All Conditions
Hidradenitis suppurativa (Skin disorder)
Dermatology
Featured Trial
High Triglyceride Clinical Research Study
Recruiting
Living with high triglycerides? See if our clinical study is right for you.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.
Conditions:
High Triglycerides
High Triglyceride Level
Hypertriglyceridemia
Elevated Triglycerides
Triglycerides High
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Recruiting
The purpose of this study is to identify the recommended dose of vudalimab to be used in combination with chemotherapy (Part 1) and to evaluate the efficacy and safety of vudalimab plus standard of care chemotherapy relative to pembrolizumab plus chemotherapy (Part 2) as first-line treatment in patients with nonsquamous non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: Mid Florida Hematology and Oncology Center, Orange City, Florida
Conditions: Nonsquamous Non-small Cell Lung Cancer
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Recruiting
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REGN2810), individually called a "study drug" or collectively called "study drugs". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC).
The aim of the study is to see how effective the combination of fianlimab and cemiplimab is in treating advanced NSCLC, in comparison with cemiplimab by itself.
The study is looking... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Mid Florida Hematology and Oncology Center, Orange City, Florida
Conditions: Advanced Non-Small Cell Lung Cancer
Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
Recruiting
The study will first determine the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving first line anti-PD(L)1 treatment for locally advanced or metastatic non-small cell lung cancer. The efficacy and safety of the combination is then compared to standard of care carboplatin and pemetrexed in the same populations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/04/2024
Locations: Mid-Florida Hematology & Oncology Centers, PA, Orange City, Florida
Conditions: Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Recruiting
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy.
Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Mid-Florida Hematology Oncology, Orange City, Florida
Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC)
13 - 16 of 16